ReviewMolecular diversity2026
The JAK/STAT pathway: a pivotal therapeutic target in disease and advances in natural product modulation.
Review in Molecular diversity, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
The JAK/STAT (Janus kinase/signal transducer and activator of transcription) signaling pathway was discovered during the investigations on cellular responses to interferons (IFNs) in the early 1990s, and its components and functions were gradually elucidated and refined in the subsequent years. Serving as a core mediator of extracellular signal transduction such as cytokines and growth factors, the JAK/STAT signaling pathway plays a pivotal role in various diseases, representing an attractive therapeutic target. Although synthetic agents targeting this pathway have demonstrated clinical efficacy, long-term administration is frequently associated with adverse effects such as immunosuppression and infection risks. In recent years, natural products have emerged as novel candidates for modulating JAK/STAT signaling pathway, owing to their structural diversity, multi-target mechanisms and low-toxicity profiles. This review offers a comprehensive elucidation of the JAK/STAT signaling pathway, covering its discovery history, core components and transmembrane signal transduction mechanisms, and underscores its essential functions in the progression of diverse diseases. Furthermore, this review focuses on summarizing the research progress on natural products that modulate the JAK/STAT pathway from 2021 to 2025, and traces the research history of related natural products. This review aims to comprehensively demonstrate the development potential of natural products as drug lead compounds targeting the JAK/STAT pathway, thereby providing a theoretical foundation for subsequent studies.
Indexed as
Identifiers
42584521What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.